SCHEMBL496542

SCHEMBL496542

CN(C)c1ccccc1-c1nnc2c3ccccc3c(Nc3cccc(N)c3)nn12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.44
POLB P06746 3/20 0.38
KDM4E B2RXH2 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
AHR P35869 1/20 0.37
MAPT P10636 4/20 0.37
TP53 P04637 2/20 0.37
TDP1 Q9NUW8 2/20 0.36
KAT2A Q92830 1/20 0.36
KAT2B Q92831 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
GFER P55789 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL496714 0.88 PDE2A (0.51) PDE2APOLBMAPTTP53KAT2A
SCHEMBL496632 0.87 MAPT (0.50) PDE2APOLBKDM4ENPSR1RXFP1
SCHEMBL12971550 0.84 TNNI3K (0.44) PDE2APOLBKDM4ENPSR1RXFP1
SCHEMBL496579 0.84 ABCG2 (0.44) PDE2APOLBKDM4ESMN1; SMN2GAA
SCHEMBL2825175 0.84 PDE2A (0.61) PDE2APOLBKDM4ENPSR1RXFP1
SCHEMBL496562 0.84 PDE2A (0.48) PDE2APOLBKDM4ENPSR1RXFP1
SCHEMBL496563 0.84 PDE2A (0.46) PDE2APOLBKDM4ENPSR1RXFP1
SCHEMBL496760 0.83 RXFP1 (0.46) PDE2ARXFP1MAPTTP53GABRA1
SCHEMBL496764 0.81 PDE2A (0.44) PDE2AAHRKAT2B
Dimethylamine SCHEMBL496544 0.81 NPC1 (0.52) POLBKDM4ENPSR1RXFP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836207-B1 TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS NYCOMED GMBH (DE) 2012-10-10 EP disclosed
US-8106047-B2 (4-Methoxyphenyl)-[3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine; phosphodiesterase inhibitors; septic shock or vascular edema; neoangiogenesis or inflammatory disease NYCOMED GMBH (DE) 2012-01-31 US disclosed
US-20080312225-A1 Triazolophthalazines NYCOMED GMBH (DE) 2008-12-18 US disclosed
EP-1836207-A2 TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS Nycomed GmbH (DE) 2007-09-26 EP disclosed
WO-2006072615-A2 TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS NYCOMED GMBH (DE) 2006-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312225-A1 Triazolophthalazines PDE2A, PDE3A, PDE12 PDE2A 1/4885POLB 1897/4885KDM4E 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.